May 1, 2018

RXi Pharma developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company’s discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune […]
April 29, 2018

Cible’s smart drug platform overcomes platinum drug resistance

Cible is a preclinical-stage cancer drug company that solves the major problems of traditional cancer therapy through the implementation of a smart drug platform. The first lead candidate, oxaliTEX, is found to be well tolerated, tumor localizing, and overcomes platinum drug resistance in pharmacological in vitro human cancer models. These […]
April 29, 2018

Tosk works to alleviate the painful, debilitating, and potentially fatal side effects of front line cancer therapies

Tosk is a dynamic drug development company dedicated to alleviating the painful, debilitating, and potentially fatal side effects of front line cancer therapies and to make certain cancer drugs effective in patients who do not currently benefit from treatment. We are developing a family of what we call CompanionTM drugs […]
April 29, 2018

TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells.

TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells.  In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor.  Additional studies have shown that SBT-1214 is able to […]
April 29, 2018

OTraces uses math/physics-based noise suppression techniques to enhance the accuracy and performance of cancer

OTraces has developed a disruptive technology using math/physics-based noise suppression techniques to enhance the accuracy and performance of cancer diagnostics. By using these techniques to access the active proteins found in the tumor microenvironment (TME) with, for the first time, simple and cost-effective blood based-tests, OTraces has solved the problem of […]
April 28, 2018

SageMedic creates a 3D micro-tumor assay to determine best cancer treatment

SageMedic is creating a 3D micro-tumor assay to help physicians determine the best cancer treatment for their patient. To do so, we take a live tumor biopsy, create hundreds of 3D micro-tumors, expose them to a wide range of anti-cancer drugs (e.g. chemotherapy or targeted therapy), and measure the response […]
April 28, 2018

Hookipa Biotech best-in-class active immunization therapies for infectious diseases and oncology

Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology.   The company’s proprietary TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most […]
April 28, 2018

CytRx Corporation Advancing Four New Linker-Activated Drug Release Candidates to IND-Enabling Studies

LADR™ Technology May Successfully Harness Potential of Known, Efficacious Anti-Cancer Compounds Whose Development Has Been Impeded CytRx Corporation (NASDAQ: CYTR), a Los Angeles-based biopharmaceutical research and development company specializing in oncology, recently selected four new investigational-stage Linker-Activated Drug Release (LADR™) candidates for advancement toward clinical testing in cancer patients.  At […]
April 28, 2018

RXi Pharmaceuticals is developing next generation immune-oncology therapeutics based on a self-delivery RNAi therapeutic platorm

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company’s discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune […]
April 28, 2018

CEL-SCI Corporation Developing Immunotherapy Products for Early Treatment of Cancer and Infectious Diseases

Multikine® Therapy Treats Newly Diagnosed Head and Neck Cancer Patients Before They Undergo Surgery, Radiation, or Chemotherapy CEL-SCI Corporation is a publicly-traded (NYSE: CVM) Phase III cancer immunotherapy company with operations in the Baltimore area.  CEL-SCI develops immunotherapy products for the treatment of cancer and infectious diseases, based on the […]
April 28, 2018

Aphios Corporation Utilizes Medicinal Plants and Marine Organisms to Develop Enabling Technology Platforms

Aphios Pharma is Now Developing Cannabis-Based Treatment for Opioid Addition Aphios Corporation is a Woburn, MA-based, clinical-stage biotechnology company that is developing green enabling technology platforms to improve drug discovery, manufacturing, nanotechnology drug delivery, and pathogenic safety.  Aphios is delivering enhanced therapeutic products to improve quality-of-life and treat chronic diseases […]
April 28, 2018

Alpha Cancer Technologies Utilizes Recombinant Human Alpha-Fetoprotein to Selectively Target and Kill Cancer Cells

Therapy Targets AFP Receptors Found in Over 80 Percent of Cancer Cells Alpha Cancer Technologies Inc. (ACT) is a Toronto-based clinical-stage biotechnology company that is developing drugs for oncology and auto-immune disease indications.  Alpha Cancer Technologies’ products include Alpha-Fetoprotein (AFP), a human protein produced by the embryo during fetal development; […]
April 28, 2018

RNA Diagnostics Delivers “Personalized Medicine” By Assessing Effectiveness of Individual Cancer Treatments

RNA Disruption Assay™ Test Can Determine Degree of Ribosomal RNA Disruption During Chemotherapy Rna Diagnostics Inc. is a Toronto-based early-stage molecular diagnostics company that is developing medical diagnostic tools to assist in the management of cancer.  The company’s first product, RNA Disruption Assay™ (RDA™), is a novel test that helps […]
April 28, 2018

20/20 GeneSystems Utilizes Continuous Machine Learning to Aid in Early Detection of Cancer

“20/20 Hindsight” Platform Improves Accuracy of Most Widely Used Cancer Biomarkers 20/20 GeneSystems, Inc. is a Rockville, MD-based, digital diagnostics company focused on reducing cancer mortality through early detection.  20/20 GeneSystems is pioneering a novel approach to cancer detection, called “20/20 Hindsight”, that uses continuous machine learning to utilize large […]
April 28, 2018

QuantumCyte Developing Innovative Tools and Workflows for Single Cell Analysis Cancer Research

Q1© Platform Takes Unique Approach to Isolation and Interrogation of Individual Cancer Cells QuantumCyte is a Silicon Valley-based early-stage biotechnology company that is developing a unique drug assay system.  QuantumCyte’s single-cell analysis system, known as Q1©, can predict drug efficacy in a way that is rapid, non-invasive, and accurate.  Q1© […]
April 27, 2018

Aurora Biopharma Developing Revolutionary CAR T Cell Therapy to Kill Cancer

CAR T Cell Therapy May Change Cancer Patients’ Own Weak T Cells into “Bionic Killing Machines” Aurora Biopharma is a Cambridge, MA-based, clinical-stage company that is developing state-of-the-art cancer immunotherapy, utilizing a form of adoptive cell transfer called Chimeric Antigen Receptor (CAR) T Cell Therapy.  The therapy genetically edits patients’ […]
April 17, 2018

Trethera Corporation Developing TRE-515 to Treat Myelodyspastic Syndromes and Acute Myeloid Leukemia

TRE-515 Therapy Targets Multiple Pathways to Improve Treatment Efficacy Over Single-Agent Approaches Trethera Corporation, a Los Angeles-based clinical-stage biopharmaceutical company, is developing cancer treatments for orphan blood cancers with high unmet needs.  Trethera’s lead program combines TRE-515, a novel deoxycytidine kinase inhibitor, with de novo pathway inhibitors. TRE-515 has been […]
April 17, 2018

Geneius Developing Innovative T-Cell Therapy that Targets Viral and Neoantigens

Targeted DiversiTy™ Therapy Promotes Surveillance and Destruction of Cancer Cells By Re-Educating Patients’ Own T Cells Geneius is an immuno-oncology company based in Natick, MA, that is focused on T-cell immunotherapies for cancer and infections.  Geneius has developed an innovative autologous, adoptive T-cell therapy technology (Targeted DiversiTy™) that promotes surveillance […]
April 17, 2018

Vitanova Biomedical Utilizes Photodynamic Therapy to Kill Aggressive Cancer Cells

Light-Activated Intracellular Acidosis Therapy May Cause Cancer Cells to Undergo Rapid Apoptosis Vitanova Biomedical Inc., a San Antonio-based early-stage biotechnology company, is currently conducting pre-clinical trials on a proprietary Light-Activated Intracellular Acidosis therapy that potentially kills multiple types of aggressive cancer cells.  Vitanova Biomedical is working with clinical research organization […]
April 17, 2018

Immunicom Developing Subtractive Device-Based Cancer Treatment Platform

Blood-Filtering Device Treats Cancer By Removing Blocking Proteins Released By Cancer Cells Immunicom Inc., a San Diego-based immuno-oncology company, is developing a proprietary subtractive device-based technology platform as a novel approach to treating cancer.  Immunicom’s immunotherapy platform (Immunopheresis™) potentially treats all cancer types and other terminal diseases through a blood-filtering […]